NCT02524769View on ClinicalTrials.gov

The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

June 30, 2017

Conditions

Overactive Bladder

Interventions

DRUG

conjugated estrogen

0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.

Trial Locations (1)

60153

Loyola University Medical Center, Maywood

All Listed Sponsors

lead

Loyola University

OTHER

NCT02524769 - The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides | Biotech Hunter | Biotech Hunter